
    
      The Phase 1 part of the study was a first-in-human, single ascending dose, double-blind,
      randomized (except Cohorts 6 to 9 [open-label]) study in healthy subjects to evaluate the
      safety, tolerability and PK of CBL-514, and to determine the dose levels to be used for the
      Phase 2a part of the study.
    
  